Hartsorb

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Hartsorb

What is Hartsorb? Definition and Classification

Property Description
Active ingredient Isosorbide Dinitrate (ISDN)
Form Tablets (Oral, Sublingual), Capsules (Extended-release)
Pharmacological Class Organic Nitrate / Vasodilator
Common Purpose Mitigating cardiovascular strain
Origin Synthetic

Hartsorb is a brand name for the prescription-only medication whose active ingredient is Isosorbide Dinitrate (ISDN), a synthetic small molecule classified within the high-level pharmacological class of Organic Nitrates.

The core function of Isosorbide Dinitrate is its ability to serve as a potent systemic vasodilator, promoting the widening of blood vessels. Organic nitrates facilitate the relaxation of vascular smooth muscle cells in both veins and arteries, acting as a nitric oxide donor. This class of medicine is recognized for its role in improving oxygen balance in the heart muscle. Furthermore, this compound is metabolized to form the active substance Isosorbide Mononitrate, contributing to its prolonged therapeutic effects. This metabolic pathway ensures the sustained presence of the active agent to continuously relieve cardiovascular strain.

Forms, Types, and General Benefit

The medication is supplied as various pharmaceutical preparations intended for oral or sublingual administration, including immediate-release tablets, sublingual tablets, and extended-release capsules.

The availability of these varying dosage forms reflects the compound's clinical need for both immediate and sustained action. The fundamental therapeutic purpose of its powerful vasodilating action is to reduce cardiovascular strain by lowering the volume of blood returning to the heart, effectively minimizing the effort required for pumping. The chief effect of this drug type is to promote the widening of the coronary arteries, enhancing blood flow to the heart muscle itself. This facilitates the balance of the supply and demand of oxygen for the heart muscle.

Regulatory References

  1. Isosorbide Dinitrate DailyMed Label (NIH)
  2. Isosorbide Mononitrate DailyMed Label (NIH)

What side effects are possible with Hartsorb?

Possible Side Effects and Safety Information

The safety profile of Hartsorb (Isosorbide Dinitrate) is formally classified in regulatory documents by the frequency and physiological system affected. The most frequently documented adverse reaction is headache, classified as very common (affecting more than 1 in 10 patients). This effect is often noted as being more frequent at the start of treatment and typically lessens over time.

Frequency and System Classification

Adverse effects listed as common (affecting up to 1 in 10 patients) primarily relate to the cardiovascular and nervous systems, including dizziness, tachycardia (increased heart rate), hypotension (low blood pressure), and nausea. Hypotension is specifically documented as being more likely during treatment initiation or dose escalation.

Less frequent effects, classified as uncommon, include syncope (fainting), vomiting, and a paradoxical effect known as angina pectoris aggravated.

Serious Reactions and Safety Constraints

Regulatory labeling identifies certain serious adverse reactions, such as severe symptomatic hypotension and syncope. Rare but serious reactions, including exfoliative dermatitis, are also documented.

Official safety restrictions note that the medication is contraindicated in patients with pre-existing conditions such as severe anemia, hypotensive shock, circulatory collapse, or increased intracranial pressure. Furthermore, regulatory notes indicate that older adults may have an increased risk of hypotension and related effects.

Overdose and Emergency Response

Hartsorb overdose manifestations are formally documented in regulatory labeling and primarily stem from profound vasodilation. Overdose may present with severe hypotension leading to a marked fall in blood pressure and often reflex tachycardia. Other documented signs include a persistent and throbbing headache, dizziness, syncope, and visual disturbances. Severe outcomes documented in regulatory sources include circulatory collapse, cardiac arrest, and a specific hematological complication, methaemoglobinaemia, which can lead to cyanosis and difficulty breathing.


Official Emergency Response

Condition or Manifestation
Suspected Overdose
Collapse, Seizure, or Breathing Trouble
Required Emergency Action (As Labeled)
Seek emergency medical treatment immediately and stop intake of the drug
Call emergency services (911) or poison control center

Treatment must be symptomatic and supportive, as no specific antagonist to the primary vasodilator effects of the medication is known. If recent ingestion of a large quantity has occurred, gastric lavage may be employed. Careful clinical and hemodynamic monitoring is required during management. Patients with underlying renal failure or congestive heart failure may require specialized monitoring during supportive volume expansion, as noted in official prescribing information.

Therapeutic Uses of Hartsorb

What Hartsorb Treats: Main Uses and Benefits

Hartsorb (isosorbide dinitrate) is commonly used to help with the long-term management of specific conditions characterized by periods of heightened symptoms affecting the cardiovascular system. The main therapeutic application is the prevention of angina pectoris (chest pain) linked to coronary artery disease. This medication class may assist with easing symptoms related to physical discomfort and is applied across domains where additional symptomatic support is needed.

This medication is commonly used across conditions presenting with acute episodes such as angina pectoris and congestive heart failure. It is also considered relevant in conditions involving episodic or fluctuating manifestations when applied in scenarios where additional management of discomfort is required. The use of this drug supports patients during episodes of heightened discomfort and may help maintain a sense of stability when symptoms become temporarily overwhelming. It is generally used for the prophylactic (preventative) management of symptoms and is relevant when supportive symptom management is appropriate.

Quick Fact: Relief for Physical Discomfort

“The use of this drug contributes to easing the overall symptom load and supports patients during episodes of heightened discomfort.”

Eligibility and Restrictions for Use

Who Can and Cannot Use Hartsorb? Official Regulatory Information

Eligibility for Hartsorb (isosorbide dinitrate) is strictly defined by regulatory authorities based on co-medication status, age, and pre-existing medical conditions.

Absolute Contraindications

Use is absolutely prohibited for patients with a known hypersensitivity to any organic nitrates, including isosorbide dinitrate. Furthermore, Hartsorb must not be used concurrently with certain medications that cause significant vasodilation:

  • Phosphodiesterase type 5 (PDE-5) inhibitors (e.g., sildenafil, tadalafil).
  • The soluble guanylate cyclase (sGC) stimulator riociguat.

Additionally, the medicine is contraindicated in patients experiencing acute circulatory failure, shock, severe hypotension, marked anemia, or conditions associated with raised intracranial pressure.

Age and Condition-Based Restrictions

Adults (18+ years) are the primary population for established use. Safety and effectiveness have not been established in pediatric patients (under 18 years). In geriatric patients, caution is noted due to potential increased sensitivity to hypotension. Use is restricted or requires caution in patients with conditions like hypertrophic obstructive cardiomyopathy, aortic stenosis, and severe hepatic or renal impairment.

Pregnancy and Lactation

Use during pregnancy is advised only if the potential benefit outweighs the potential risk to the fetus, as adequate, controlled studies are unavailable (classified as Category C). Caution is advised during lactation, as it is not known if the drug is excreted in human milk.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section describes officially documented interaction patterns for Hartsorb (Isosorbide Dinitrate) based on regulatory information, focusing on required restrictions and effects on co-administered substances.

Formal Contraindications

The co-administration of Hartsorb with certain medicines is strictly prohibited due to the potential for severe, life-threatening hypotension and cardiovascular events, representing a potent pharmacodynamic interaction. This includes all Phosphodiesterase Type 5 (PDE5) Inhibitors (e.g., Sildenafil, Tadalafil, Vardenafil) and the soluble guanylate cyclase stimulator Riociguat. These combinations are formally classified as contraindicated in official prescribing information.

Pharmacodynamic Interactions

Concurrent use with other substances that lower blood pressure may result in additive hypotensive effects. This applies to many classes of antihypertensive drugs, including beta-blockers and calcium channel blockers, and may lead to marked symptomatic orthostatic hypotension. Alcohol (ethanol) also exhibits an additive vasodilating effect, which can intensify hypotension.

Exposure Modification and Other Interactions

Regulatory documents note that Hartsorb may increase the blood level of the drug Dihydroergotamine. No mandatory time-separation rules are explicitly mandated for co-administered medicines, nor are specific interactions with food or non-government-approved herbal products formally established in major regulatory labeling.

Mechanism of Action

How Hartsorb Works


Hartsorb (Isosorbide Dinitrate) functions as a prodrug, requiring bioactivation to release the active molecule, Nitric Oxide ( NO). This NO rapidly activates the enzyme soluble Guanylyl Cyclase ( sGC) inside vascular smooth muscle cells, leading to an increase in the secondary messenger, cyclic GMP ( cGMP), which is the direct molecular signal for relaxation.

The cGMP cascade induces relaxation predominantly in the venous system, causing blood to pool in the periphery. This peripheral pooling lowers the volume and pressure of blood returning to the heart, a key physiological change known as reduction of cardiac preload, which results in a reduction in myocardial wall tension. The drug's mechanism also contributes to a degree of arterial and coronary vasodilation.

The efficacy of this mechanism is constrained by the development of nitrate tolerance, a biological phenomenon where the ability of the vessel wall to generate NO is reduced with continuous exposure. The action is sustained by the drug's metabolism into Isosorbide Mononitrate, which also contributes to the NO mechanism, which contributes to a sustained period of vascular tone modulation.

Dosage and Administration Information

Hartsorb (Isosorbide Dinitrate) administration follows distinct protocols based on the dosage form, which include oral use for chronic management and sublingual use for rapid administration.

Administration Routes and Scheduling

The immediate-release tablets and extended-release capsules are used for prophylactic scheduling. For long-term use, the primary instruction is the mandatory inclusion of a nitrate-free interval in the daily regimen. This cyclic dosing pattern is essential to maintain the medicine’s long-term utility. Immediate-release tablets are taken two or three times daily, but doses are scheduled unevenly to guarantee a required dose-free period, which often spans 14 hours or more.

The sublingual tablets, typically 2.5 mg to 5 mg, are administered by being placed and dissolved under the tongue and are not intended to be swallowed whole. This route is used on an as-needed basis for acute administration.

Preparation and Procedural Conditions

Extended-release capsules must be swallowed whole and should not be crushed or chewed, as this alters the intended sustained release. The medication can generally be taken without regard to meals. If a scheduled oral dose is missed, the standard instruction is to skip the forgotten dose and resume the next scheduled dose at the correct time; doubling the dose is not advised.

Population-Specific Use

Dose selection for older adults often begins at the low end of the maintenance range, adhering to the principle of cautious titration. For patients with renal or hepatic impairment, potential adjustments to the dose or frequency may be necessary.

Recent Clinical Evidence

Research evidence / Overview of Studies for Hartsorb


Evidence for use in Prophylactic Management of Angina Pectoris

Research exploring the use of Hartsorb in the context of managing chest pain (angina pectoris) primarily involves short-term clinical trials. These studies observed adults with stable angina, a condition characterized by fluctuating symptoms linked to effort. Researchers tracked symptom-related measures, such as the number of anginal episodes and the need for relief-providing medications. Findings described patterns where the research measured changes in the time to the onset of chest pain during controlled exercise tests.

A significant factor characterized by the research is that the development of diminished effects with continuous administration (known as tolerance) was a primary focus of study design and data analysis. Research explored the need for a rest period or drug-free interval in the regimen to maintain the observed functional patterns. Beyond this factor, long-term outcomes for patients with angina are not fully established. The current evidence base provides limited information for long-term outcomes on major cardiac events, as the focus of most trials was short-term symptom patterns.


Evidence for use in Chronic Heart Failure

For chronic heart failure (specifically when the heart's pumping ability is reduced), the most detailed research involves Hartsorb being used as part of a fixed combination with Hydralazine. These research efforts were studied for symptom change and used large-scale, long-term Randomized Controlled Trials (RCTs) to monitor critical outcomes. The research monitored all-cause mortality and heart failure-related hospitalization rates in specific patient populations.

The strongest evidence for differences in outcomes for heart failure applies only to the populations studied in the major trials, which, in a key pivotal study, specifically involved self-identified African American patients. The evidence is based on the fixed combination of the two drugs; outcomes for Hartsorb used alone in this severe condition are still emerging. Research is ongoing to better characterize the results across broader demographics.


The Landscape of Research Uncertainty

While research provides substantial context on the use of Hartsorb, several key areas remain targets for further research. One significant limitation is that the primary evidence of differences in outcomes for heart failure is based on the fixed combination; comparative evidence for Hartsorb as a single agent in this condition is lacking. Additionally, the research remains insufficient to fully characterize long-term outcomes on major cardiovascular events for angina. Finally, there is limited information available for certain groups to fully characterize outcomes.

Frequently Asked Questions (FAQ)

Common questions about Hartsorb (FAQ)

Q: Is Hartsorb a type of pain reliever?

A: Hartsorb is officially classified as a vasodilator belonging to the organic nitrate class. Its purpose is to relieve angina (chest pain) by reducing the workload on the heart. It is not generally categorized as a pain reliever for conditions outside of cardiovascular strain.

Q: How quickly should I expect to see an effect from Hartsorb?

A: The time it takes to see an effect depends on the form used. Sublingual tablets, which dissolve under the tongue, have a rapid onset of action, typically working in less than 10 minutes for acute, as-needed relief. The regular oral tablet or capsule forms are used for daily, long-term prevention and are not the indicated dosage form for acute relief.

Q: Does Hartsorb cause you to gain weight?

A: Weight gain is not listed among the commonly reported side effects in the official clinical trial data. However, a very small number of patients have reported experiencing edema (swelling or fluid retention).

Q: Does Hartsorb affect my ability to drive or operate machinery?

A: Yes, regulatory warnings advise caution when driving or operating machinery. This is because Hartsorb can cause side effects such as dizziness, lightheadedness, or hypotension (low blood pressure), which could impair a person's ability to perform these tasks safely.

Q: Does taking Hartsorb cause fatigue or sleepiness?

A: Official adverse event data indicates that fatigue and somnolence (sleepiness) have been reported, but they are not among the most common effects. These side effects were reported by a small percentage of patients in clinical studies.

Q: What should I do if a side effect seems mild but bothersome?

A: Official guidance states that patients should not unilaterally stop or change the dose of the medicine, even if they experience mild side effects like a headache. If a side effect becomes bothersome, patients are generally advised by official sources to consult their healthcare provider for guidance.

Q: How long after starting Hartsorb can I expect to reach the full effect?

A: When Hartsorb is used for the chronic prevention of conditions like angina, the full therapeutic effect is expected once a regular dosing schedule has been established. The total time required to observe the drug’s full therapeutic effect is dependent upon maintaining the regular, continuous dosing schedule and the necessary dose-free interval.

Q: What is the difference between an adverse reaction and a common side effect for Hartsorb?

A: In official regulatory documents, adverse reactions are generally listed and classified by how frequently they occurred in clinical studies. The most frequent reactions—like headache and dizziness—are often referred to as common side effects in patient materials. Official safety data often categorizes effects by seriousness and frequency.

Q: What is the process for reporting a side effect I experience with Hartsorb?

A: The process for reporting a suspected side effect involves submitting information to the relevant country’s regulatory authority. For example, in the United States, this includes using the FDA’s MedWatch system.

Q: Are there any specific safety monitoring steps recommended when using Hartsorb?

A: Official safety information notes that specific monitoring may be recommended. Due to the risk of hypotension (low blood pressure), a healthcare provider may closely monitor a patient’s blood pressure, especially when treatment begins. Patients with severe liver or kidney conditions may also require close observation.

Q: What is the risk of dependence or addiction with Hartsorb?

A: Official labeling contains warnings about potential physical dependence in specific circumstances. This phenomenon has been reported in industrial workers exposed to high levels of organic nitrates, where sudden withdrawal led to cardiac events.

Q: Does Hartsorb interact with common over-the-counter pain relievers?

A: Official regulatory documents do not list the most common over-the-counter pain relievers (like ibuprofen or naproxen) as a major, high-risk interaction. However, available information suggests that isosorbide dinitrate may potentially increase the risk of liver toxicity associated with Acetaminophen (paracetamol).

Q: Can I take Hartsorb if I have diabetes?

A: Diabetes is not listed as a contraindication (a condition that strictly prohibits use) on the current official labeling for the approved uses of Hartsorb. No special warnings or use restrictions related solely to diabetes are noted.

Q: Is Hartsorb approved in countries outside of the United States?

A: Yes, the active ingredient in Hartsorb, Isosorbide Dinitrate, is approved and utilized in many countries worldwide. It is featured in the official formularies and guides of various health systems, including those in the United Kingdom.

Q: What is the expected duration of treatment with Hartsorb?

A: Hartsorb is commonly prescribed for the long-term prevention (prophylaxis) of chronic cardiovascular conditions, such as angina. The specific duration of treatment is determined by the prescribing healthcare provider, based on the patient’s diagnosis and condition.

Q: How does the mechanism of Hartsorb differ from older treatments for the same condition?

A: Official documents describe Hartsorb as a vasodilator that works by releasing Nitric Oxide to relax blood vessels. It is classified as an Organic Nitrate, which is a mechanism often recognized for the treatment of angina.

Q: Can Hartsorb make an existing mental health condition worse?

A: Official adverse event reports list certain psychiatric effects, such as anxiety, confusion, and depression, as potential side effects. These effects were reported by a small number of patients in clinical trials (5% or less).

Q: Is it safe to stop using Hartsorb suddenly?

A: Official guidance notes that patients should avoid suddenly stopping the regular use of this medicine. Abrupt discontinuation may potentially increase the risk of chest pain or result in a rebound effect on the cardiovascular system.

Q: Does Hartsorb have any known long-term side effects that appear after years of use?

A: Some research suggests that the continuous, long-term use of organic nitrates may potentially impair endothelial function (the health of the inner lining of blood vessels) in some patients with coronary artery disease. Patients are generally advised to consult their healthcare provider for specific information regarding long-term risks.

Q: Is there a list of all known medicines that interact with Hartsorb?

A: Official regulatory documents identify high-risk interactions by listing the entire drug classes that are strictly prohibited (e.g., PDE5 inhibitors). They also list specific drugs or classes with moderate interaction risk. The documents focus on officially identified interactions rather than a fully exhaustive list of every known generic or brand name.

Q: What is the meaning of the term 'contraindication' related to Hartsorb?

A: A contraindication is a medical term used in official labeling to mean a specific situation or pre-existing condition that absolutely prohibits the use of a medicine. For Hartsorb, this includes using it with certain other vasodilating medicines or having certain severe cardiovascular conditions.

Q: What is known about how Hartsorb is eliminated from the body?

A: Hartsorb is known to be metabolized (broken down) in the body to form another active substance, Isosorbide Mononitrate, which contributes to its therapeutic effect. The final elimination of the medicine and its metabolites is primarily through the kidneys.

How should Hartsorb be stored and disposed of?

Official Storage Requirements

Condition Requirement
Temperature Store at controlled room temperature, typically between 15 C and 30 C.
Environment Must be protected from excessive moisture and direct light.
Prohibitions Do not freeze and keep the product away from excessive heat.
Packaging Store in the original container, ensuring the container is tightly closed and light-resistant.

Disposal and Safety Rules

Official labeling mandates that all medicine, unused or expired, must be kept out of the reach of children.

Disposal must be completed according to government-mandated requirements. The product should not be flushed down a toilet or poured into a drain unless specifically instructed by an official medication guide. Contact a healthcare professional or local waste authority for guidance on appropriate collection points or take-back programs to ensure compliance with all environmental regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Hartsorb found in:

A-Z Index: